Transitional Drugs 3
- Published
- 14 May 2025
- Estimated value
- £29,045,630
- Place of performance
- UKL
- Procedure
- Open procedure
- Lots
- 1
- Notice number
- 021504-2025
- Reference
- ocds-h6vhtk-04c9a9
- Official source
- Official source
Description
Drugs which have recently lost their patent exclusivity
Awards
| Awarded to | Amount | Date |
|---|---|---|
| Celltrion Healthcare Uk Ltd | — | — |
| Biogen Idec Ltd | — | — |
| Celix Pharma | — | — |
| Roche Products Ltd | — | — |
| Sandoz Ltd | — | — |
| Sun Pharma Ltd | — | — |
| Zentiva Ltd | — | — |
| Amgen Ltd | — | — |
| Fresenius Kabi Ltd | — | — |
| Thornton & Ross Ltd | — | — |
Official publications
- FTS · 021504-2025 · 14 May 2025
Other tenders from Velindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on behalf of All Wales UHBs & Trusts
Frequently asked questions
- What is the estimated value of this tender?
- The estimated value published by the buyer is £29,045,630.
- Who is the buyer of this tender?
- The contracting authority is Velindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on behalf of All Wales UHBs & Trusts (United Kingdom).
- How can I bid for public tenders in the United Kingdom?
- Bids are submitted through the official public procurement portal in the United Kingdom. El Vínculo helps you find tenders and analyse their documents; submission always happens at the official source.
Get alerts for tenders like this
Create a free account and receive new public tenders published in the United Kingdom that match your business, every day.
Create a free account and receive new public tenders published in the United Kingdom that match your business, every day.